| Literature DB >> 35568796 |
Ahmed Rafee1,2, Sarah Riepenhausen3, Philipp Neuhaus3, Alexandra Meidt3, Martin Dugas4, Julian Varghese5.
Abstract
BACKGROUND: Screening for eligible patients continues to pose a great challenge for many clinical trials. This has led to a rapidly growing interest in standardizing computable representations of eligibility criteria (EC) in order to develop tools that leverage data from electronic health record (EHR) systems. Although laboratory procedures (LP) represent a common entity of EC that is readily available and retrievable from EHR systems, there is a lack of interoperable data models for this entity of EC. A public, specialized data model that utilizes international, widely-adopted terminology for LP, e.g. Logical Observation Identifiers Names and Codes (LOINC®), is much needed to support automated screening tools.Entities:
Keywords: Data models; Eligibility screening; LOINC; Medical informatics; UMLS
Mesh:
Year: 2022 PMID: 35568796 PMCID: PMC9107639 DOI: 10.1186/s12874-022-01611-y
Source DB: PubMed Journal: BMC Med Res Methodol ISSN: 1471-2288 Impact factor: 4.612
Fig. 3Diagrammatic representation of the distribution of clinical domains in MeSH terms among EC forms. MeSH: Medical Subject Headings
Fig. 1Schematic representation of the semi-automated method used in this analysis. MDR: Metadata Repository; MDM: Medical Data Models Portal; EC: Eligibility Criteria; UMLS: Unified Medical Language System; MRCONSO: a UMLS table for concept names and sources; MRSTY: a UMLS table for semantic types; SLC: Secondary Laboratory Concept; PLC: Primary Laboratory Concept; LOINC: Logical Observation Identifiers Names and Codes; MII: German Medical Informatics Initiative [63, 64]; ODM: Operational Data Model; CSV: Comma-Separated Values
Fig. 2Manually analyzed concept of Bilirubin, Total Measurement. The row at the bottom shows mapping of PLC to LOINC (Further LOINC details were omitted from the image but can still be found in the dataset). PLC: Primary Laboratory Concept; STR: string (definition); n: frequency of individual concept; STY: Semantic Type; nTotal: Sum of all n’s (PLC and SLCs)
Fig. 4Graph showing the cumulative total frequencies among the 58 aggregated set of LP in terms of nTotal, i.e. after manual analysis and combining of all n values of PLC and SLCs for each laboratory concept. Analyzed laboratory concepts that have an nTotal above 50 concepts cover the steepest change of the slope of cumulative frequencies (Orange). Based on this, we have only included the first 55 analyzed concepts that have nTotal above 50. Blue bars show the nTotal of each analyzed laboratory concept
Fig. 5Plot diagram showing the coverage of laboratory concepts within the group of laboratory semantic types (Group A). 311 laboratory concepts representing our 55 LP cover 77.87% of all concept occurrences in group A. n: Frequency of Individual Concept
Top 55 screening LP ranked according to total frequencies. LP are listed using UMLS and LOINC Terminologies
| Rank | 1ry LOINC Code | UMLS Lab. Procedure | UMLS Definition | nTotal |
|---|---|---|---|---|
| 1 | 59,826–8 | C3525719 | Measurement of creatinine in blood | 1817 |
| 2 | 7918–6 | C3714540 | HIV Antibody Measurement | 1670 |
| 3 | 13,955–0 | C0201487 | Hepatitis C antibody measurement | 1595 |
| 4 | 76,625–3 | C0201836 | Alanine aminotransferase measurement | 1464 |
| 5 | 63,557–3 | C0201477 | Hepatitis B surface antigen measurement | 1462 |
| 6 | 2106–3 | C0546577 | HCG Pregnancy Test | 1383 |
| 7 | 26,515–7 | C0032181 | Platelet Count measurement | 1381 |
| 8 | 1920–8 | C0201899 | Aspartate aminotransferase measurement | 1303 |
| 9 | 54,363–7 | C0201913 | Bilirubin, total measurement | 1265 |
| 10 | 4548–4 | C0474680 | Hemoglobin A1c measurement | 1021 |
| 11 | 59,260–0 | C0518015 | Hemoglobin measurement | 968 |
| 12 | 26,511–6 | C0948762 | Absolute neutrophil count | 851 |
| 13 | 2164–2 | C0373595 | Creatinine clearance measurement | 758 |
| 14 | 15,074–8 | C0392201 | Blood glucose measurement | 633 |
| 15 | 69,405–9 | C3811844 | Estimated Glomerular Filtration Rate | 513 |
| 16 | 26,464–8 | C0023508 | White Blood Cell Count procedure | 487 |
| 17 | 19,197–3 | C0201544 | Prostate specific antigen measurement | 471 |
| 18 | 77,145–1 | C0428568 | Fasting blood glucose measurement | 400 |
| 19 | 5010–4 | C1533728 | Hepatitis C virus genotype determination | 352 |
| 20 | 72,383–3 | C5189164 | HER2 in tissue by immunoassay | 324 |
| 21 | 1783–0 | C0201850 | Alkaline phosphatase measurement | 287 |
| 22 | 14,130–9 | C3811131 | Estrogen Receptor Measurement | 283 |
| 23 | 10,676–5 | C1868902 | HCV viral load | 257 |
| 24 | 70,218–3 | C0202236 | Triglycerides measurement | 195 |
| 25 | 6298–4 | C0729816 | Blood potassium measurement | 194 |
| 26 | 34,714–6 | C0525032 | International Normalized Ratio | 191 |
| 27 | 40,557–1 | C0373717 | Progesterone receptor assay | 180 |
| 28 | 1996–8 | C0201925 | Calcium measurement | 171 |
| 29 | 5964–2 | C0033707 | Prothrombin time assay | 137 |
| 30 | 14,913–8 | C0853134 | blood testosterone measurement | 131 |
| 31 | 54,347–0 | C0201838 | Albumin measurement | 130 |
| 32 | 14,647–2 | C0201950 | Cholesterol measurement test | 130 |
| 33 | 22,748–8 | C0202117 | Low density lipoprotein cholesterol measurement | 126 |
| 34 | 69,739–1 | C0202274 | Urine drug screen | 124 |
| 35 | 26,446–5 | C2697913 | Leukemic Blast Count | 122 |
| 36 | 1986–9 | C0202100 | Insulin C-peptide measurement | 118 |
| 37 | 13,954–3 | C3835873 | Serum Hepatitis B E Antigen, qualitative | 113 |
| 38 | 3015–5 | C0202230 | Thyroid stimulating hormone measurement | 111 |
| 39 | 50,564–4 | C0042014 | Urinalysis | 102 |
| 40 | 33,763–4 | C1533071 | N terminal pro-brain natriuretic peptide level | 99 |
| 41 | 82,904–4 | C2074589 | chromosome studies Philadelphia | 95 |
| 42 | 20,570–8 | C0018935 | Hematocrit procedure | 93 |
| 43 | 3173–2 | C0030605 | Activated Partial Thromboplastin Time measurement | 93 |
| 44 | 83,098–4 | C0202022 | Follicle stimulating hormone measurement | 83 |
| 45 | 53,962–7 | C0201539 | Alpha one fetoprotein measurement | 80 |
| 46 | 10,438–0 | C3540684 | CD20 Expressing Cell Measurement | 76 |
| 47 | 76,485–2 | C0201657 | C-reactive protein measurement | 74 |
| 48 | 58,410–2 | C0009555 | Complete Blood Count | 71 |
| 49 | 42,595–9 | C3641250 | Hepatitis B DNA Measurement | 68 |
| 50 | 14,646–4 | C0428472 | Serum HDL cholesterol measurement | 63 |
| 51 | 20,564–1 | C0523807 | Oxygen saturation measurement | 60 |
| 52 | 30,395–8 | C0857490 | Granulocyte count | 58 |
| 53 | 29,760–6 | C0201916 | Bilirubin, direct measurement | 53 |
| 54 | 72,903–8 | C0005845 | Blood urea nitrogen measurement | 51 |
| 55 | 1992–7 | C0201924 | Calcitonin measurement | 50 |
Fig. 6Screenshot of the dataset on MDM portal showing available download formats e.g. ODM and FHIR